Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis?

@article{Cappelli2014IsIT,
  title={Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis?},
  author={Susanna Cappelli and S Bellando-Randone and Serena Guiducci and Marco Matucci-Cerinic},
  journal={Rheumatology},
  year={2014},
  volume={53 6},
  pages={975-87}
}
Since activation of the immune system and a perivascular infiltrate of inflammatory cells are key features of SSc, immunosuppression has long been considered to be an anchor treatment. Non-selective immunosuppression remains central to the treatment of interstitial lung disease (ILD) and skin involvement, with CYC most widely used to obtain remission. The use of MTX as a first-line agent may be considered in the presence of skin involvement without ILD. More recently, MMF has shown encouraging… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
8 Citations
95 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 95 references

The ASTIS trial: autologous stem cell transplantation versus IV pulse cyclophosphamide in poor prognosis systemic sclerosis, first results [abstract

  • JM van Laar, D Farge, JK Sont
  • Ann Rheum Dis 2012;
  • 2012

Efficacy of cyclophosphamide in the treatment of interstitial lung disease associated with systemic sclerosis

  • G Espinosa, CP Simeón, MÁ Plası́n
  • Arch Bronconeumol
  • 2011

Similar Papers

Loading similar papers…